Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2006 1
2008 5
2009 5
2010 11
2011 20
2012 17
2013 8
2014 11
2015 6
2016 10
2017 8
2018 5
2019 7
2020 9
2021 8
2022 8
2023 17
2024 14
2025 12
2026 6

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

158 results

Results by year

Filters applied: . Clear all
Page 1
Showing results for ambrose, cs
Search for Ambroset CS instead (1 results)
Efficacy of Tezepelumab in Severe, Uncontrolled Asthma: Pooled Analysis of the PATHWAY and NAVIGATOR Clinical Trials.
Corren J, Menzies-Gow A, Chupp G, Israel E, Korn S, Cook B, Ambrose CS, Hellqvist Å, Roseti SL, Molfino NA, Llanos JP, Martin N, Bowen K, Griffiths JM, Parnes JR, Colice G. Corren J, et al. Among authors: ambrose cs. Am J Respir Crit Care Med. 2023 Jul 1;208(1):13-24. doi: 10.1164/rccm.202210-2005OC. Am J Respir Crit Care Med. 2023. PMID: 37015033 Free PMC article. Clinical Trial.
An expert consensus framework for asthma remission as a treatment goal.
Menzies-Gow A, Bafadhel M, Busse WW, Casale TB, Kocks JWH, Pavord ID, Szefler SJ, Woodruff PG, de Giorgio-Miller A, Trudo F, Fageras M, Ambrose CS. Menzies-Gow A, et al. Among authors: ambrose cs. J Allergy Clin Immunol. 2020 Mar;145(3):757-765. doi: 10.1016/j.jaci.2019.12.006. Epub 2019 Dec 19. J Allergy Clin Immunol. 2020. PMID: 31866436 Free article. Review.
Clinical response and on-treatment clinical remission with tezepelumab in a broad population of patients with severe, uncontrolled asthma: results over 2 years from the NAVIGATOR and DESTINATION studies.
Wechsler ME, Brusselle G, Virchow JC, Bourdin A, Kostikas K, Llanos JP, Roseti SL, Ambrose CS, Hunter G, Jackson DJ, Castro M, Lugogo N, Pavord ID, Martin N, Brightling CE. Wechsler ME, et al. Among authors: ambrose cs. Eur Respir J. 2024 Dec 5;64(6):2400316. doi: 10.1183/13993003.00316-2024. Print 2024 Dec. Eur Respir J. 2024. PMID: 39326921 Free PMC article. Clinical Trial.
Efficacy of Tezepelumab in Patients with Severe, Uncontrolled Asthma Across Multiple Clinically Relevant Subgroups in the NAVIGATOR Study.
Carr TF, Moore WC, Kraft M, Brusselle G, Castro M, Chupp GL, Wechsler ME, Hunter G, Lindsley AW, Llanos JP, Burke LK, Chandarana S, Ambrose CS. Carr TF, et al. Among authors: ambrose cs. Adv Ther. 2024 Jul;41(7):2978-2990. doi: 10.1007/s12325-024-02889-8. Epub 2024 May 27. Adv Ther. 2024. PMID: 38802635 Free PMC article. Clinical Trial.
Editorial.
Ambrose CS, Bhattacharya J, Fox CB, McIntosh ED, Stern PL. Ambrose CS, et al. Ther Adv Vaccines. 2013 May;1(1):3-5. doi: 10.1177/2051013613486264. Ther Adv Vaccines. 2013. PMID: 24757511 Free PMC article. No abstract available.
Effect of Tezepelumab on Sino-Nasal Outcome Test (SNOT)-22 Domain and Symptom-Specific Scores in Patients with Severe, Uncontrolled Asthma and a History of Chronic Rhinosinusitis with Nasal Polyps.
Jacobs JS, Han JK, Lee JK, Laidlaw TM, Martin NL, Caveney S, Ambrose CS, Martin N, Spahn JD, Hoyte FCL. Jacobs JS, et al. Among authors: ambrose cs. Adv Ther. 2025 Jan;42(1):510-522. doi: 10.1007/s12325-024-03006-5. Epub 2024 Nov 8. Adv Ther. 2025. PMID: 39514041 Free PMC article. Clinical Trial.
158 results